Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

December 31, Top 20 Shareholders

201231_Top_Holders_Report (91)

Categories: News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard January 4, 2021

Related posts

March 31, Top 20 Shareholders
April 1, 2021

February 28, Top 20 Shareholders
March 1, 2021

January 31, Top 20 Shareholders
February 1, 2021

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
December 23, 2020

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

December 21, Epichem Awarded DNDi Extension
December 21, 2020

Recent Articles

April 8, PharmAust Receives $750k R&D Tax Incentive Refund
April 8, 2021
April 7, LUMC: Monepantel Testing Indicates Anti-Covid19 Activity
April 7, 2021
March 31, Top 20 Shareholders
April 1, 2021
March 31, Monepantel Phase IIb Dog Lymphoma Trial Update
March 31, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

Retweet on Twitter PharmAust Retweeted

PharmAust @PharmAust·

Aim to extend a dog’s life

Via @StirlingTimes

Reply on Twitter 1382483167441944577 Retweet on Twitter 13824831674419445774 Like on Twitter 138248316744194457711 Twitter 1382483167441944577

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions